<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276883</url>
  </required_header>
  <id_info>
    <org_study_id>BXCL501-302</org_study_id>
    <nct_id>NCT04276883</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder</brief_title>
  <acronym>SERENITY II</acronym>
  <official_title>A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine Efficacy and Safety of BXCL501 In Agitation Associated With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioXcel Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cognitive Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioXcel Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the
      acute treatment of agitation in bipolar disorder. The BXCL501-302 study is designed to
      characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of
      DEX, HCl) in agitation associated with bipolar disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll approximately 375 subjects randomized 1:1:1 to dose regimens of 180µg,
      120µg BXCL501, or placebo stratified by age &lt; 65 and age ≥ 65. Male and female adults with
      acute agitation associated with bipolar disorder will be enrolled. Eligible subjects (acutely
      agitated subjects with bipolar disorder, generally hypomanic, manic or mixed episodes) may be
      identified in outpatient clinics, mental health, psychiatric or medical emergency services
      including medical/psychiatric observation units, or as newly admitted to a hospital setting
      for acute agitation or already in hospital for chronic underlying conditions. Subjects will
      be domiciled in a clinical research setting or hospitalized to remain under medical
      supervision while undergoing screening procedures to assess eligibility. Efficacy and safety
      assessments will be conducted periodically before and after dosing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>phase III, randomized, double-blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary End Point</measure>
    <time_frame>120 minutes</time_frame>
    <description>Absolute change from baseline in the PEC score at 2 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key Secondary Endpoint</measure>
    <time_frame>120 minutes</time_frame>
    <description>Earliest time where an effect on agitation is apparent as measured by change from baseline PEC total score in contrast with placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Agitation Associated With Bipolar Disorder</condition>
  <condition>Agitation,Psychomotor</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>120 Micrograms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual film containing 120 Micrograms Dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 Micrograms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual film containing 180 Micrograms Dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sublingual placebo film</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual film containing Dexmedetomidine (BXCL501)</intervention_name>
    <description>Sublingual film containing Dexmedetomidine (BXCL501)</description>
    <arm_group_label>120 Micrograms</arm_group_label>
    <arm_group_label>180 Micrograms</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Film</intervention_name>
    <description>Placebo Film for BXCL501</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients between the ages of 18 to 75 years, inclusive.

          2. Patients who have met DSM-5 criteria for bipolar I or II disorder.

          3. Patients who are judged to be clinically agitated at Screening and Baseline with a
             total score of ≥ 14 on the 5 items (poor impulse control, tension, hostility,
             uncooperativeness, and excitement) comprising the PANSS Excited Component (PEC).

          4. Patients who have a score of ≥ 4 on at least 1 of the 5 items on the PEC at Baseline.

          5. Patients who read, understand and provide written informed consent.

          6. Patients who are in good general health prior to study participation as determined by
             a detailed medical history, physical examination, 12-lead ECG with rhythm strip, blood
             chemistry profile, hematology, urinalysis, and in the opinion of the Principal
             Investigator.

          7. Participants who agree to use a medically acceptable and effective birth control
             method

        Exclusion Criteria:

          1. Patients with agitation caused by acute intoxication, including positive
             identification of alcohol by breathalyzer or drugs of abuse (with the exception of
             THC) during urine screening.

          2. Use of benzodiazepines or other hypnotics or oral or short-acting intramuscular
             antipsychotic drugs in the 4 hours before study treatment.

          3. Treatment with alpha-1 noradrenergic blockers (terazosin, doxazosin, tamsulosin,
             alfuzosin, or prazosin) or other prohibited medications.

          4. Patients who are judged to be at significant risk of suicide.

          5. Female patients who have a positive pregnancy test at screening or are breastfeeding.

          6. Patients who have hydrocephalus, seizure disorder, or history of significant head
             trauma, stroke, transient ischemic attack, subarachnoid bleeding, brain tumor,
             encephalopathy, meningitis, Parkinson's disease or focal neurological findings.

          7. History of syncope or other syncopal attacks, current evidence of hypovolemia,
             orthostatic hypotension.

          8. Patients with laboratory or ECG abnormalities considered clinically significant by the
             investigator.

          9. Patients with serious or unstable medical illnesses.

         10. Patients who have received an investigational drug within 30 days prior to the current
             agitation episode.

         11. Patients who are considered by the investigator, for any reason, to be an unsuitable
             candidate for receiving DEX.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andressa de Oliveira</last_name>
    <phone>475-238-6837</phone>
    <email>adoliveira@bioxceltherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cedirc Burg</last_name>
    <phone>475-238-6837</phone>
    <email>cburg@bioxceltherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-238-6837</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

